KRAS and colorectal carcinoma: To further identify the subset-specific therapeutic agents for KRAS-mutant CRC subtypes, we applied three drug response databases (CTRP-v2, PRISM and GDSC1) to investigate the potential therapeutic agents of KM1 and KM2 cell subsets (Figure 7C).